Homozygous Familial Hypercholesterolemia (HoFH) Overview
Learn About Homozygous Familial Hypercholesterolemia (HoFH)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
San Tan Cardiovascular Center LLC
Elena Carretta is a Nurse Practitioner in Mesa, Arizona. Carretta and is rated as an Experienced provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). Her top areas of expertise are Heterozygous Familial Hypercholesterolemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH). Carretta is currently accepting new patients.
San Tan Cardiovascular Center LLC
Zelalem Yilma is a Cardiologist in Mesa, Arizona. Dr. Yilma and is rated as an Experienced provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). Her top areas of expertise are Angina, Arterial Embolism, Acute Coronary Syndrome, Pacemaker Implantation, and Heart Bypass Surgery. Dr. Yilma is currently accepting new patients.
Kerry S Green MD Plc
Kerry Green is a Family Medicine provider in Mesa, Arizona. Dr. Green and is rated as an Advanced provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are Homozygous Familial Hypercholesterolemia (HoFH), Hyperlipoproteinemia Type 4, Heterozygous Familial Hypercholesterolemia (HeFH), and Defective Apolipoprotein B-100.
Summary: Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series ...
Summary: This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR mutations. NGGT006 is an adeno-associated viral (AAV) vector carrying codon-optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoti...